Last reviewed · How we verify
Period 1: Abiraterone
At a glance
| Generic name | Period 1: Abiraterone |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer (PHASE1)
- Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer (EARLY_PHASE1)
- A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (PHASE3)
- Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer (PHASE1)
- Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide (PHASE2)
- COMbination of Bipolar Androgen Therapy and Nivolumab (PHASE2)
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects (PHASE1)
- A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Period 1: Abiraterone CI brief — competitive landscape report
- Period 1: Abiraterone updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI